4D Molecular Therapeutics, Inc. short interest in 2024
In 2024, 4D Molecular Therapeutics, Inc.'s disclosed short interest ran from 6.74% of shares outstanding on 12 Jan 2024 to 15.72% on 15 Nov 2024, a change of +8.98 percentage points. The year's high was 21.95% on 30 Sep 2024 and its low 6.74% on 12 Jan 2024, averaging 17.81% across 21 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 23.17 days on 13 Sep 2024. Full history: 4D Molecular Therapeutics, Inc..
Cite this page
By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026
2024 in figures
- Start of year
- 6.74% (12 Jan 2024)
- End of year
- 15.72% (15 Nov 2024)
- Change
- +8.98 pp
- High
- 21.95% (30 Sep 2024)
- Low
- 6.74% (12 Jan 2024)
- Average
- 17.81%
- Highest days to cover
- 23.17 (13 Sep 2024)
- SEC filings marked
- 8
Every report in 2024
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 12 Jan 2024 | 6.74% | 8.25 | |
| 31 Jan 2024 | 8.97% | 7.96 | |
| 15 Feb 2024 | 16.52% | 1.98 | |
| 29 Feb 2024 | 16.76% | 12.29 | 10-K filed, results (8-K) |
| 15 Mar 2024 | 17.08% | 9.91 | |
| 28 Mar 2024 | 18.72% | 13.84 | |
| 15 Apr 2024 | 19.76% | 12.11 | |
| 30 Apr 2024 | 19.33% | 22.18 | |
| 15 May 2024 | 19.38% | 22.89 | 10-Q filed, results (8-K) |
| 31 May 2024 | 19.24% | 19.93 | |
| 14 Jun 2024 | 19.49% | 16.53 | |
| 28 Jun 2024 | 19.87% | 10.88 | |
| 15 Jul 2024 | 20.78% | 18.88 | |
| 31 Jul 2024 | 19.15% | 4.69 | |
| 15 Aug 2024 | 20.00% | 17.14 | 10-Q filed, results (8-K) |
| 30 Aug 2024 | 19.84% | 21.96 | |
| 13 Sep 2024 | 19.12% | 23.17 | |
| 30 Sep 2024 | 21.95% | 7.64 | |
| 15 Oct 2024 | 19.07% | 10.39 | |
| 31 Oct 2024 | 16.44% | 11.03 | |
| 15 Nov 2024 | 15.72% | 9.53 | 10-Q filed, results (8-K) |
See also: 4D Molecular Therapeutics, Inc.'s full history · most shorted US stocks of 2024 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.